Inspiration Healthcare Group PLC · LSE:IHC
Inspiration Healthcare — FY2025 Earnings Presentation
26 slides from Inspiration Healthcare's earnings presentation, May 2025
Slide 1: Inspiration Healthcare Group plc FY25 Preliminary Results Presentation
Inspiration Healthcare Group plc FY25 Preliminary Results Presentation “Pioneering medical technology starting with the very first breaths of life” Raffi Stepanian – CEO May 2025 Alan Olby - CFO Innovate | Create | Inspire
Slide 2: Disclaimer
Disclaimer While the information contained herein has been prepared by Inspiration Healthcare Group plc (“Inspiration”) in good faith, neither it nor any of its directors, officers, agents, advisers, affiliates or employees makes any representation or warranty, express or implied, nor shall any of t
Slide 3: Agenda
Agenda 1. FY25 Highlights 2. FY25 Financial Review 3. Business Overview & Trends 4. Outlook and Q&A 5. Appendices 3 Innovate | Create | Inspire
Slide 4: FY25 in Summary
FY25 in Summary Operational Highlights Financial Highlights FY25 • Award of two material export contracts for SLE 6000 & 1500 • Revenues increased 2% to £38.2m • Appointments of CCO, Tech Support, Customer Support • Neonatal sales decreased by 15% • Transfer of Viomedex from Hailsham to Asia – annua
Slide 5: 'Back to Basics' – from Stabilisation to Performing
’Back to Basics’ – from Stabilisation to Performing 4. EXECUTE FUTURE STRATEGY 1. DRIVE SALES Back to Basics 2. INCREASE PROFITS 3. IMPROVE WORKING CAPITAL 5 Innovate | Create | Inspire
Slide 6: Agenda
Agenda 1. FY25 Highlights 2. FY25 Financial Review 3. Business Overview & Trends 4. Outlook and Q&A 5. Appendices 6 Innovate | Create | Inspire
Slide 7: FY25 Financials Summary
FY25 Financials Summary Revenue £38.3m (FY24: £37.6m) Gross 42.8% Operating £(1.5)m Margin (FY24: 47.5%) Cash Flow (FY24 £2.0m) Adjusted £0.2m Net £8.3m EBITDA1 (FY24: £2.0m) Debt2 (FY24: £6.0m) Operating £(14.7m) Loss (FY24: (£4.9m)) 1 Earnings before interest, tax, depreciation, amortisation, impa
Slide 8: FY25 Revenue
FY25 Revenue UK/Ire sales declined 10% as a result of NHS budget pressures and sales team restructure International sales decline of 17% due to end-of-life of some legacy products and lack of customer engagement Airon contribution of £2.4m for full year exceeded expectations Infusion product revenue
Slide 9: FY25 Income Statement
FY25 Income Statement FY25 FY24 £’000 £’000 Revenue 38,251 37,630 Gross Profit 16,378 17,887 • Gross margin reduction due to sales mix, lower capital sales and inventory provisions Gross margin 42.8% 47.5% for end-of-life products Admin. expenses pre non-recurring items (18,262) (18,287) • Operating
Slide 10: FY25 Movement in Net Debt
FY25 Movement in Net Debt • Net debt increased by £2.3m over the year to £8.3m • Restructuring costs, capex, interest and lease payments account for bulk of the movement • Offset by £2.7m received from June 24 equity raise • Working capital flat as inventory reduction offset by increase in receivabl
Slide 11: Agenda
Agenda 1. FY25 Highlights 2. FY25 Financial Review 3. Business Overview & Trends 4. Outlook and Q&A 5. Appendices 11 Innovate | Create | Inspire
Slide 12: Serving Three Distinct Markets
Serving Three Distinct Markets Inspiration Healthcare designs, manufactures and markets pioneering medical technology that saves lives and improves the outcomes of patients starting with the very first breath of life • Own Brand capital and consumable products with IP Neonatal Intensive Care • Distr
Slide 13: Key Trends FY26 & Beyond: Market & Portfolio Evolution
Key Trends FY26 & Beyond: Market & Portfolio Evolution Changing Underlying Continuous Margin Market landscape demand Development improvement development - Regulatory -Neonatal - Re-launch of - Better product - North America SLE1500 & geography mix - Restrengthen restrictions ventilation remains - Ne
Slide 14: Continued 'Back to Basics'
Continued ’Back to Basics’ 1. DRIVE SALES • Improve geographic spread 4. EXECUTE FUTURE STRATEGY • Increase distributor sales in Int’l region. • Reassess vision & strategy Team structured – recruiting AsiaPac • Already engaged Key Opinion manager Leader as consultant • Win fair share in Europe with
Slide 15: Agenda
Agenda 1. FY25 Highlights 2. FY25 Financial Review 3. Business Overview & Trends 4. Outlook and Q&A 5. Appendices 15 Innovate | Create | Inspire
Slide 16: Positive Outlook – Back to Basics Driving Results
Positive Outlook – Back to Basics Driving Results Positive financials with strong H1 - Large Middle East & Humanitarian Organisation contracts on track - Opportunity pipeline providing confidence in full-year market expectations - Working Capital improvement with inventory decreasing - Net Debt redu
Slide 17: Questions ?
Questions ? 17 Innovate | Create | Inspire
Slide 18: Appendix
APPENDIX 18 Innovate | Create | Inspire
Slide 19: Broad Portfolio of Innovative, Specialist Products
Broad Portfolio of Innovative, Specialist Products Key Neonatal Products Key Infusion Products Key Airon Products Breathing Circuits SLE Ventilators Rythmic Serena Rythmic Ultima pNeuton Model A pNeuton Mini First BreathTM nCPAP Parenteral Nutrition PCA Pain Inspire nCPAPTM Management Inspire rPAPTM
Slide 20: Neonatal Intensive Care: A Growing Core Market Despite Changing Market Dynamics
Neonatal Intensive Care: A Growing Core Market Despite Changing Market Dynamics Global Growth Drivers Changing Market Dynamics • Saturation in adult ventilation market driving new entrants resulting in more aggressive Increase in healthcare Increase in premature competition in neonatal segment infra
Slide 21: Infusion Therapies: A Significant Opportunity
Infusion Therapies: A Significant Opportunity UK and Ireland Market Growth Market Opportunities Drivers NHS desire to get patients home New products with superior features earlier - including remote monitoring Technology advancements – remote monitoring of equipment Expansion into new therapy areas
Slide 22: Specialty Ventilators: A Significant Opportunity
Specialty Ventilators: A Significant Opportunity Global Growth Drivers Market Opportunities Unique pneumatic technology ideal Leverage IHC global distribution for transport and MRI network to increase footprint Synergies with core neonatal Expansion into new therapy areas ventilation segment (MRI, T
Slide 23: Customer in Focus
Customer in Focus Foreca Supply sting Accuracy Chain Planning nt Spare pme sS e Shi ks < 2 w hip c vi 8 we e ee me ks n De < t g eerin Cus rocesses Re-engin ce Tech ess Simplifica g < 24 ho Time Co ndling Support excellen Ha llence Exc urs Proc mpl Response e Support Resourcin aint P r i o rit <10 r
Slide 24: Revenue by Geography
Revenue by Geography FY25: FY24: FY23: Domestic £20.3m 53% 50% 48% (FY24: £18.7m) FY25: FY24: FY23: Europe £5.6m 15% 12% 13% (FY24: £4.4m) FY25: FY24: FY23: Americas £3.5m 9% 5% 3% (FY24: £1.9m) FY25: FY24: FY23: Asia Pacific £6.0m 15% 22% 23% (FY24: £8.4m) Mid East & Africa £2.9m FY25: FY24: FY23:
Slide 25: FY25 Cashflow Statement
FY25 Cashflow Statement FY25 FY24 £’000 £’000 Cash (used in)/generated from operations (1,462) 1,822 Taxation paid (87) 190 Net cash (used in)/generated from operating • Cash outflow from operations resulting from (1,549) 2,012 activities restructuring charges, working capital flat and remains eleva
Slide 26: Balance Sheet
Balance Sheet 31 Jan 25 31 Jan 24 £’000 £’000 Intangible assets • £10.3m impairment to goodwill and acquired Non-current assets 15,931 25,993 intangibles • £0.7m reduction in inventory Inventories 13,083 13,743 Trade and other receivables 11,336 8,669 • Receivables increased due to high Q4 sales Net
Inspiration Healthcare Group — FY2025 Earnings Presentation on 6ix